View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
February 18, 2022updated 08 Mar 2022 9:16am

Germany accounts for 3.9% share of global clinical trial activity in 2021

By Carmen

Germany has accounted for a 3.9% share of the global clinical trials activity in 2021, registering a decrease when compared with the last ten-year average of a 6.0% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Germany

Industry sponsored trials held an 87.6% share of all the clinical trials in Germany in 2021, when compared with the ten-year average of 88.1%. Non-industry sponsored trials accounted for a 12.4% share in 2021 as against the average of 11.9% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in Germany

Oncology was the leading therapy area for industry sponsored clinical trials in Germany in 2021 with a 28.6% share, as against a five-year average of 30.6% and a ten-year average of 29.4%.

Central Nervous System held an 11.5% share in 2021, over a five-year average of 11.1% and a ten-year average of 11.6%.

Infectious Disease held a 9.9% share in 2021, compared to a five-year average of 6.6% and a ten-year average of 8.3%. Immunology held a 9.2% share in 2021, as against a five-year average of 9.6% and a ten-year average of 9.2%.

Metabolic Disorders held a 7.1% share, over a five-year average of 8.4% and a ten-year average of 8.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in Germany

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in Germany in 2021 with a 30.3% share, as against a five-year average of 11.5% and a ten-year average of 10.6%.

Oncology held a 25.4% share in 2021, over a five-year average of 21.0% and a ten-year average of 24.0%.

Central Nervous System held a 20.5% share in 2021, compared to a five-year average of 24.0% and a ten-year average of 26.3%. Gastrointestinal held a 6.6% share in 2021, as against a five-year average of 6.3% and a ten-year average of 6.2%.

Cardiovascular held a 5.7% share, over a five-year average of 12.5% and a ten-year average of 14.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead industry sponsored clinical trials in Germany in 2021

Phase II trials held a 39.1% share of industry sponsored clinical trials in Germany in 2021, over a five-year average of 37.2% and a ten-year average of 34.9%.

Phase III trials held a 39.1% share in 2021, as against a five-year average of 38.6% and a ten-year average of 38.9%. Phase IV trials held an 11.5% share in 2021, compared to a five-year average of 9.9% and a ten-year average of 12.4%.

Phase I trials held a 10.2% share in 2021, over a five-year average of 14.3% and a ten-year average of 13.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in Germany in 2021

Phase II trials held a 50.0% share of non-industry sponsored clinical trials in Germany in 2021, over a five-year average of 55.3% and a ten-year average of 51.0%.

Phase IV trials held a 28.7% share in 2021, as against a five-year average of 22.4% and a ten-year average of 23.5%. Phase III trials held a 13.1% share, compared to a five-year average of 14.1% and a ten-year average of 15.9%.

Phase I held an 8.2% share in 2021, over a five-year average of 8.2% and a ten-year average of 9.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU